GE HealthCare Announces Cash Dividend for Third Quarter of 2023

CHICAGO–(BUSINESS WIRE)–The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC), a leading medical technology, pharmaceutical diagnostics, and digital solutions innovator, today declared a cash dividend of $0.03 per share of Common Stock for the third quarter of 2023 payable on November 15, 2023 to all shareholders of record as of October 20, 2023.

About GE HealthCare

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are an $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.

Contacts

Investor Relations Contact:
Carolynne Borders

+1-631-662-4317

carolynne.borders@gehealthcare.com

Media Contact:
Tor Constantino

+1-585-441-1658

tor.constantino@gehealthcare.com

Staff

Recent Posts

AARC Celebrates Introduction of the SOAR Act in the House of Representatives

Bill passage key to supplemental oxygen access and adequate reimbursementIRVING, TX / ACCESSWIRE / March…

2 hours ago

She Is Not Skipping a Beat, and Patients Are Noticing

NORTHAMPTON, MA / ACCESSWIRE / March 26, 2024 / Quest Diagnostics At Quest for 2…

2 hours ago

Innovaccer Launches AI Advisory Board to Drive Advances in Artificial Intelligence

Expanding its roster of technology leaders will enhance its ability to drive innovation and deliver…

5 hours ago

Virtual Second Opinions Save Over $8,700 Per Patient, New Analysis Finds

Third-party research confirms significant impact of specialty expertise on patients’ quality of life and costs…

5 hours ago

BioFuse Medical Technologies Appoints Dr. David Battleman as Chief Executive Officer

Proven healthcare executive and life sciences strategist joins to bring groundbreaking BioFuse Multi-Tissue Welder (MTW)…

5 hours ago